Unicycive Therapeutics Inc
NASDAQ:UNCY

Watchlist Manager
Unicycive Therapeutics Inc Logo
Unicycive Therapeutics Inc
NASDAQ:UNCY
Watchlist
Price: 5.69 USD 0.71% Market Closed
Market Cap: 122.3m USD

Unicycive Therapeutics Inc
Investor Relations

Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. The company is headquartered in Los Altos, California and currently employs 9 full-time employees. The company went IPO on 2021-06-17. The firm is focused on identifying medical conditions within and outside of kidney disease. Its development programs are focused on the development of two therapies: Renazorb, for treatment of hyperphosphatemia in patients with chronic kidney disease, and UNI 494, for treatment of acute kidney injury (AKI). Renazorb was initially developed by, and licensed from, Spectrum Pharmaceuticals. UNI 494 was initially developed by, and licensed from Sphaera Pharmaceuticals, respectively.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Dr. Shalabh K. Gupta M.D., MPA
Founder, Chairman, CEO & President
No Bio Available
Dr. Pramod Gupta Ph.D.
Executive Vice President of Pharmaceutical & Business Operations
No Bio Available
Mr. Douglas Jermasek M.B.A.
Executive Vice President of Corporate Strategy
No Bio Available
Mr. John W. Townsend CPA
Chief Financial Officer
No Bio Available

Contacts

Address
CALIFORNIA
Los Altos
4300 El Camino Real, Suite 210
Contacts
+16503840642.0
unicycive.com